Shanghai Serum Bio-Technology Co Ltd. Stock Analysis 688163.SS

Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, and sell preventive and therapeutic drugs for biotoxins and biosafety. The company is headquartered in Shanghai, Shanghai and currently employs 330 full-time employees. The company went IPO on 2022-03-11. The firm is mainly engaged in the research, development, manufacturing and sales of preventive and therapeutic drugs as well as rapid diagnostic products for the field of biotoxins and biosafety. The firm's main products include anti-pit viper venom, anti-five-step snake venom, anti-bungi venom, anti-cobra venom, equine immunoglobulin and anti-rabies serum. The firm's products are mainly used for emergency snakebite treatment. The firm mainly conducts its businesses in the domestic market.